Tirzepatide | Advanced Dual GIP/GLP-1 Research Compound
Original price was: $350.00.$332.00Current price is: $332.00.
Tirzepatide is a synthetic peptide studied as a first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Often referred to in literature as a “twincretin,” it is a 39-amino acid modified peptide based on the native GIP sequence. In advanced metabolic research, Tirzepatide is investigated for its synergistic ability to improve glycemic control and modulate energy balance with greater efficacy than single-receptor agonists.
Tirzepatide: The Science of Synergistic Incretin Agonism
The Biochemistry of Tirzepatide
The structure of Tirzepatide ($C_{225}H_{348}N_{48}O_{68}$) incorporates a C20 fatty diacid moiety attached via a linker, which allows for high-affinity binding to albumin. This acylation significantly extends its half-life to approximately 5 days, facilitating sustained signaling in research models. While based on the GIP backbone, its sequence is meticulously engineered to provide potent activity at both the GIP and GLP-1 receptors.
Mechanism of Action: Dual-Receptor Signaling
In advanced endocrinology and pharmacology research, Tirzepatide functions through two primary coordinated pathways:
-
GIP Receptor Agonism: The peptide mimics native GIP to enhance insulin secretion in a glucose-dependent manner and is studied for its unique role in improving adipose tissue insulin sensitivity and buffering postprandial lipids.
-
GLP-1 Receptor Agonism: By engaging the GLP-1R, Tirzepatide is observed to suppress glucagon secretion, delay gastric emptying, and act on the central nervous system to induce satiety.
-
Synergistic Metabolic Control: Research suggests that the GIP component may offset some of the gastrointestinal limitations of GLP-1 signaling while enhancing the overall anorexigenic and glycemic benefits.
Primary Research Applications
-
Metabolic Syndrome & Type 2 Diabetes: Analyzing the restoration of beta-cell function and the stabilization of hemoglobin A1c levels.
-
Chronic Weight Management Research: Investigating the impact of dual signaling on total body fat mass, visceral adiposity, and energy expenditure.
-
Cardiometabolic Health: Studying the peptide’s effects on lipid profiles, blood pressure, and markers of systemic inflammation.
-
NASH/MASH Research: Observing the impact of dual incretin agonism on hepatic fat accumulation and fibrosis markers.
4. Technical Specifications (E-E-A-T Data)
| Feature | Scientific Specification |
| Peptide Type | Dual GIP and GLP-1 Receptor Agonist |
| Amino Acid Count | 39 Amino Acids |
| Molecular Formula | $C_{225}H_{348}N_{48}O_{68}$ |
| Molecular Weight | 4813.5 g/mol |
| CAS Number | 2023788-19-2 |
| Purity Grade | $\geq$99% (HPLC & Mass Spec Verified) |
| Modification | C20 fatty diacid acylation |
| Solubility | Soluble in Water and Saline |
5. Product FAQ
Q: Why is Tirzepatide called a “Dual” agonist?
A: It is termed a dual agonist because it activates two different incretin receptors—GIP and GLP-1—simultaneously. Research indicates this dual action addresses more metabolic pathways than agonists that only target a single receptor.
Q: How does the C20 fatty diacid affect Tirzepatide in research?
A: The C20 fatty diacid moiety allows the peptide to bind reversibly to albumin in the blood. This prevents rapid renal clearance and enzymatic degradation, providing a long half-life suitable for weekly observation cycles in laboratory models.
Only logged in customers who have purchased this product may leave a review.
Related products
GROWTH HORMONE RESEARCH PEPTIDES
Hexarelin | Advanced GHRP & Growth Hormone Research Compound
NEUROPEPTIDE RESEARCH COMPOUNDS
NEUROPEPTIDE RESEARCH COMPOUNDS
RESEARCH-GRADE COMPOUNDS
EMERGING & SPECIALIST RESEARCH PEPTIDES
Follistatin 344 | Advanced Myostatin Inhibition Research Data
RESEARCH-GRADE COMPOUNDS
RESEARCH-GRADE COMPOUNDS
GLP-1 & METABOLIC RESEARCH COMPOUNDS
Reviews
There are no reviews yet.